Related Experiment Video

Updated: Jun 16, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers

Naga Meka1, Srikanth Katragadda, Biju Cherian

  • 1Department of Cardiology, Rosalind Franklin University, North Chicago VA Medical Center, IL 60064, USA.

American Journal of Therapeutics
|January 22, 2010
PubMed

Insights

Many adults have hypertension, and monotherapy often fails. Combining calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs) effectively lowers blood pressure with fewer side effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension affects one-third of US adults and is a major risk factor for cardiovascular events.
  • Current blood pressure control in hypertensive patients is frequently inadequate, falling below recommended goals.
  • Monotherapy is insufficient for nearly half of patients with hypertension.

Purpose of the Study:

  • To review clinical trials supporting the need for combination therapy in hypertension management.
  • To focus on the combination of calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs).

Main Methods:

  • Review of clinical trials investigating hypertension treatment strategies.
  • Analysis of studies comparing monotherapy with combination therapy, specifically CCBs and ARBs.

Main Results:

  • Combination therapy is recommended when blood pressure exceeds goals by 20/10 mm Hg.
  • The combination of ARBs and CCBs offers complementary blood pressure-lowering effects.
  • This combination demonstrates a lower incidence of adverse effects compared to high-dose monotherapy.

Conclusions:

  • Combination therapy, particularly with ARBs and CCBs, is essential for achieving blood pressure control in many hypertensive patients.
  • The synergistic action of ARBs and CCBs provides enhanced efficacy and improved safety profiles.
  • This approach addresses the limitations of monotherapy and improves cardiovascular risk management.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...